Novo Nordisk's new CagriSema obesity drug trial to begin on Feb. 10, clinicaltrials.gov entry shows
Novo Nordisk will begin a new late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10, ...
Novo Nordisk will test CagriSema's long-term efficacy in late-stage trial, clinicaltrials.gov entry shows
Novo Nordisk will begin a late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10 to test its ...
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Novo Nordisk To Contact Him Directly To Discuss Their ...
The Schall Law Firm Invites Shareholders With Losses To Lead A Securities Fraud Case Against Novo Nordisk A/S
LOS ANGELES, CA / ACCESS Newswire / February 2, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...
Novo Nordisk says it has not yet posted details about new CagriSema trial
Novo Nordisk said on Thursday it has not yet posted details about a new trial of its experimental next-generation obesity drug CagriSema, which it announced it would start after late-stage trial data ...
Reuters4d
Novo Nordisk will test CagriSema's long-term efficacy in late-stage trial, clinicaltrials.gov entry shows
LONDON, Jan 30 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab will begin a late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10 to test its long-term efficacy ...
Novo Nordisk Shares Have a Long Road Back from 40% Slump
Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But ...
Novo Nordisk Hit With Suit for Underwhelming CagriSema Trial (1)
A Novo Nordisk A/S investor says the pharmaceutical company’s failure to disclose how it tested experimental obesity shot ...
devdiscourse3d
Novo Nordisk Commences Fresh Trials for CagriSema
Novo Nordisk announced further trials of its obesity drug, CagriSema, following unsatisfactory results from a previous phase. A new Phase III trial will assess long-term efficacy, launching on ...
BioSpace9d
Novo Rebounds as Next-Gen Obesity Drug Elicits up to 22% Weight Loss
The readout comes on the heels of CagriSema’s disappointing Phase III performance, where it missed Novo’s projection of 25% ...
MM&M9d
Novo Nordisk’s amycretin cuts weight by 22% in early obesity trial
The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.
Morningstar10d
Novo Nordisk: Next-Generation GLP-1/Amylin Drug Sees Leading Weight Loss in Small Trial
The amycretin data looks stronger than the 19% weight loss at 36 weeks generated for Lilly’s next-generation drug retatrutide in phase 2 (phase 3 data is expected in 2026) and 20.4% cagrisema ...